Neodolpasse (Diclofenac Sodium, Orphenadrine Citrate)

Diclofenac sodium and orphenadrine citrate, the active ingredients in Neodolpasse, are a non‑steroidal anti‑inflammatory drug and an anticholinergic muscle relaxant presented as an injectable solution for intravenous use. They are indicated for post‑operative pain, acute musculoskeletal pain and muscle spasm in adult patients. Neodolpasse is marketed in the European Union and complies with EU pharmaceutical standards.

GNH USA supplies Neodolpasse as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neodolpasse combines an NSAID and a centrally acting muscle relaxant to manage pain and spasm in acute musculoskeletal conditions.

- Post‑operative pain: provides analgesia and reduces inflammation after surgery. - Acute musculoskeletal pain: alleviates pain and swelling associated with injuries or strain. - Muscle spasm: relaxes skeletal muscle and diminishes involuntary contractions.

Neodolpasse may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild stomach upset. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Injection site pain: local discomfort at the IV site. - Elevated liver enzymes: mild, reversible changes. - Gastrointestinal discomfort: mild dyspepsia.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Gastrointestinal bleeding: black stools or vomiting blood. - Hepatotoxicity: significant liver injury. - Renal impairment: reduced kidney function. - Cardiac events: increased risk of myocardial infarction. - Severe hypotension: sudden drop in blood pressure.

Before using Neodolpasse, consider the following safety measures.

- Assess renal function: avoid in severe renal impairment. - Evaluate hepatic status: use cautiously in liver disease. - Monitor cardiovascular risk: contraindicated in patients with recent myocardial infarction. - Check for hypersensitivity: avoid if known allergy to diclofenac, orphenadrine, or other NSAIDs. - Use with caution in elderly: increased susceptibility to adverse effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neodolpasse can interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or COX‑2 inhibitors: heightened gastrointestinal toxicity. - Lithium: diclofenac may raise lithium levels. - Methotrexate: reduced clearance leading to toxicity. - ACE inhibitors or diuretics: potential renal function decline.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: modest increase in bleeding tendency. - Corticosteroids: additive risk of gastrointestinal ulceration. - Antihypertensives: possible reduction in blood pressure control. - Diabetic agents: may affect glucose regulation. - Other anticholinergics: enhanced anticholinergic side effects.